The life sciences industry experienced a dynamic year in 2024. As the public markets gained traction, IPO activity and venture investment saw ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The split will allow WBD to take advantage of "broader market opportunities" as they arise, CEO David Zaslav told analysts.

BTIG initiated coverage of Novavax (NVAX) with a Buy rating and $19 price target The company’s standalone COVID vaccine seems to be a ...

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

Transitioned lead commercial responsibility of Nuvaxovid COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in ...

Novavax Inc (NASDAQ:NVAX) reported fourth-quarter 2024 sales of $88.31 million, compared to $291 million a year, beating the ...

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

Novavax reported $88 million in revenues in the fourth quarter, compared to $291 million the year prior, and $682 million for ...

Novavax (NVAX) stock jumped today following the release of the vaccine maker’s Q4 2024 earnings report. That follows its diluted earnings per ...

Shares of Novavax (NASDAQ:NVAX) rose about 1.75% in premarket trading after reporting a smaller-than-expected quarterly loss but it missed revenue estimates. The company is transitioning away from ...